Recurrent GBM Stem Cell Tumor Amplified RNA Immunotherapy Trial
Recurrent GBM Stem Cell Tumor Amplified RNA Immunotherapy Trial is a PHASE1 clinical asset sponsored by John Sampson in Recurrent Central Nervous System Neoplasm. SEO and diligence focus: BTSC mRNA-loaded DCs, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Recurrent Central Nervous System Neoplasm
Modality: RNA therapy
Target: BTSC mRNA-loaded DCs
Sponsor: John Sampson
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BTSC mRNA-loaded DCs
View original source fields
Condition raw: Recurrent Central Nervous System Neoplasm
Condition normalized: Recurrent Central Nervous System Neoplasm
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: BTSC mRNA-loaded DCs
Target normalized: BTSC mRNA-loaded DCs